Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC — Stella

Recruiting

Back to Papillary Renal Cell Carcinoma Type 2 trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(12 sites)

France

Ico - Paul Papin, Angers

CHU de BESANCON, Besançon

Chu Bordeaux, Bordeaux

Centre Jean Perrin, Clermont-Ferrand

Centre Leon Berard, Lyon

Key details

Phase

Safety & dosing

Sponsor

Centre Leon Berard

Enrollment target

~72 participants

Started

June 2022

Primary completion

October 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated January 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov